

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



国药集团  
SINOPHARM

# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)*  
(Stock Code: 01099)

## ANNOUNCEMENT

### PRINCIPAL UNAUDITED FINANCIAL DATA OF CNMDC FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement dated 24 October 2024 (the “**Announcement**”) issued by Sinopharm Group Co. Ltd. (the “**Company**”), in relation to the Company’s subsidiary China National Medical Device Co., Ltd. (中國醫療器械有限公司) (“**CNMDC**”)’s and its consolidated unaudited balance sheet, income statement and cash flow statement for the nine months ended 30 September 2024 (the “**Reporting Period**”).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of CNMDC for the Reporting Period as set out in the Announcement.

\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.

## PRINCIPAL CONSOLIDATED UNAUDITED FINANCIAL DATA OF CNMDC

*Unit: Yuan  
Currency: RMB*

	<b>Reporting Period</b>	<b>Same period of last year</b>	<b>Changes of this period over the same period of last year (%)</b>
Revenue	56,045,505,051.00	60,222,491,361.81	-6.94
Operating profit	1,073,122,928.71	1,685,362,312.34	-36.33
Total comprehensive income attributable to owners of the parent company	406,294,708.29	678,080,902.76	-40.08
Net cash flow arising from operating activities	-8,182,735,498.07	-6,784,371,538.48	20.61

  

	<b>At the end of the Reporting Period</b>	<b>At the beginning of the Reporting Period</b>	<b>Changes of this period-end over the beginning of this period (%)</b>
Total assets	63,519,605,102.91	57,791,918,661.02	9.91
Total equity attributable to owners of the parent company	7,889,457,466.10	7,716,613,619.48	2.24

By order of the Board  
**Sinopharm Group Co. Ltd.**  
**Zhao Bingxiang**  
*Chairman*

Shanghai, the PRC  
24 October 2024

*As at the date of this announcement, the executive director of the Company is Mr. Lian Wanyong; the non-executive directors of the Company are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.*